Dr. Raj Chovatiya discusses the safety and efficacy of dupilumab for atopic dermatitis, asthma, and chronic rhinosinusitis as well as its broad potential for treating other conditions affected by the IL-4/IL-13 signaling pathway. Based on the presentation "Dupilumab: Going Beyond Atopic Dermatitis" at the Diversity in Dermatology 2022 Conference.
